Zhenzhen Fu Selected Research

globalagliatin

12/2020

Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhenzhen Fu Research Topics

Disease

5	Insulin Resistance 01/2022 - 01/2016
5	Type 2 Diabetes Mellitus (MODY) 01/2022 - 07/2016
4	Obesity 01/2022 - 01/2020
2	Rare Diseases (Rare Disease) 01/2022 - 01/2020
2	Diabetes Mellitus 01/2022 - 10/2020
2	Metabolic Diseases (Metabolic Disease) 03/2021 - 01/2020
2	Weight Loss (Weight Reduction) 02/2021 - 10/2020
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 01/2016
2	Hypoxia (Hypoxemia) 01/2014 - 10/2013
2	Pulmonary Hypertension 01/2014 - 10/2013
1	Hyperinsulinism (Hyperinsulinemia) 01/2022
1	Neoplasms (Cancer) 01/2022
1	Prediabetic State (Prediabetes) 01/2022
1	Sphingolipidoses (Sphingolipidosis) 01/2022
1	Hypertriglyceridemia 12/2020
1	Hypoglycemia (Reactive Hypoglycemia) 12/2020
1	Metabolically Benign Obesity 11/2020
1	Body Weight (Weight, Body) 10/2020
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2020
1	Cholesteryl Ester Transfer Protein Deficiency 01/2020
1	Abetalipoproteinemia (Bassen Kornzweig Syndrome) 01/2020
1	Hypobetalipoproteinemias (Hypobetalipoproteinemia) 01/2020
1	Atherosclerosis 01/2018
1	Hypothyroidism 11/2017
1	Dyslipidemias (Dyslipidemia) 07/2016
1	Glucose Intolerance 01/2016
1	Inflammation (Inflammations) 01/2016
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2016
1	Pheochromocytoma 03/2013
1	Thyroid Neoplasms (Thyroid Cancer) 03/2013
1	Multiple Endocrine Neoplasia Type 2a (MEN 2) 03/2013
1	Brain Ischemia (Cerebral Ischemia) 04/2012
1	Hyperplasia 01/2012
1	Edema (Dropsy) 01/2012
1	Bronchiectasis 01/2012
1	Residual Neoplasm 02/2010
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2010

Drug/Important Bio-Agent (IBA)

8	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 07/2016
4	LipidsIBA 03/2021 - 07/2016
4	CholesterolIBA 02/2021 - 01/2016
2	Insulin (Novolin)FDA Link 01/2022 - 01/2016
2	SphingolipidsIBA 03/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 03/2021 - 01/2018
2	Lipoproteins (Lipoprotein)IBA 01/2020 - 01/2018
2	oxidized low density lipoproteinIBA 11/2017 - 07/2016
2	Branched-Chain Amino AcidsIBA 07/2016 - 01/2016
2	Serotonin (5 Hydroxytryptamine)IBA 01/2014 - 10/2013
1	polydopamineIBA 01/2022
1	AntibodiesIBA 01/2022
1	AntigensIBA 01/2022
1	Bile Acids and Salts (Bile Acids)IBA 01/2022
1	Dopamine (Intropin)FDA LinkGeneric 01/2022
1	GlycosphingolipidsIBA 01/2022
1	Lysergic Acid Diethylamide (LSD)IBA 01/2022
1	Valine (L-Valine)FDA Link 01/2022
1	Blocking AntibodiesIBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 03/2021
1	globalagliatinIBA 12/2020
1	GlucokinaseIBA 12/2020
1	RNA (Ribonucleic Acid)IBA 11/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	BilirubinIBA 01/2020
1	AntioxidantsIBA 01/2020
1	Proprotein Convertase 9IBA 01/2018
1	LDL CholesterolIBA 07/2016
1	HDL CholesterolIBA 07/2016
1	Triglycerides (Triacylglycerol)IBA 07/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	TRPC6 Cation ChannelIBA 01/2014
1	cholesteryl-6-pyrenylhexanoate (ChPH)IBA 10/2013
1	DNA (Deoxyribonucleic Acid)IBA 03/2013
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 03/2013
1	Codon (Codons)IBA 03/2013
1	salicylhydroxamic acid (SHAM)IBA 04/2012
1	CollagenIBA 01/2012

Therapy/Procedure

2	Bariatric Surgery 10/2020 - 01/2020
1	Immunotherapy 01/2022
1	Therapeutics 01/2022
1	Gastrectomy 10/2020
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 10/2020
1	Ligation 04/2012
1	Traction 01/2012
1	Hematopoietic Stem Cell Transplantation 02/2010